These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33672694)

  • 21. Synthesis and biological activities of topopyrones.
    Zaleski PA; Maini R; Leiris SJ; Elban MA; Hecht SM
    J Nat Prod; 2012 Apr; 75(4):577-85. PubMed ID: 22462811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
    Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
    Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors.
    Legina MS; Nogueira JJ; Kandioller W; Jakupec MA; González L; Keppler BK
    J Biol Inorg Chem; 2020 May; 25(3):451-465. PubMed ID: 32193613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2,4-Diaryl-5,6-dihydro-1,10-phenanthroline and 2,4-diaryl-5,6-dihydrothieno[2,3-h] quinoline derivatives for topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
    Thapa P; Karki R; Yoo HY; Park PH; Lee E; Jeon KH; Na Y; Cho WJ; Kwon Y; Lee ES
    Bioorg Chem; 2012 Feb; 40(1):67-78. PubMed ID: 22000119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, computational study and biological evaluation of 9-acridinyl and 1-coumarinyl-1,2,3-triazole-4-yl derivatives as topoisomerase II inhibitors.
    Abdel-Hafez GA; Mohamed AI; Youssef AF; Simons C; Aboraia AS
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):502-513. PubMed ID: 35012398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES
    Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 9-Bromo-2,3-diethylbenzo[de]chromene-7,8-dione (MSN54): A novel non-intercalative topoisomerase II catalytic inhibitor.
    Mai YW; Liang CC; Ou JB; Xie HT; Chen SB; Zhou DC; Yao PF; Huang ZS; Wang H; Huang SL
    Bioorg Chem; 2021 Sep; 114():105097. PubMed ID: 34171594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases.
    Khadka DB; Tran GH; Shin S; Nguyen HT; Cao HT; Zhao C; Jin Y; Van HT; Chau MV; Kwon Y; Le TN; Cho WJ
    Eur J Med Chem; 2015 Oct; 103():69-79. PubMed ID: 26334499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
    Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
    Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
    Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in silico assessment of DNA interaction, topoisomerase I and II inhibition properties of chrysosplenetin.
    Şöhretoğlu D; Barut B; Sari S; Özel A; Arroo R
    Int J Biol Macromol; 2020 Nov; 163():1053-1059. PubMed ID: 32673727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
    Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel diindoloazepinone derivatives as DNA minor groove binding agents with selective topoisomerase I inhibition: Design, synthesis, biological evaluation and docking studies.
    Kadagathur M; Devi GP; Grewal P; Sigalapalli DK; Makhal PN; Banerjee UC; Bathini NB; Tangellamudi ND
    Bioorg Chem; 2020 Jun; 99():103629. PubMed ID: 32272367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents.
    Zembower DE; Xie Y; Koohang A; Kuffel MJ; Ames MM; Zhou Y; Mishra R; Mar AA; Flavin MT; Xu ZQ
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1117-31. PubMed ID: 22339065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of acetylcholinesterase and mammalian DNA topoisomerases, carbonic anhydrase inhibition profiles, and cytotoxic activity of novel bis(α-aminoalkyl)phosphinic acid derivatives against human breast cancer.
    Dastan T; Kocyigit UM; Durna Dastan S; Canturk Kilickaya P; Taslimi P; Cevik O; Koparir M; Orek C; Gulçin İ; Cetin A
    J Biochem Mol Toxicol; 2017 Nov; 31(11):. PubMed ID: 28833991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
    Zhang X; Wang R; Zhao L; Lu N; Wang J; You Q; Li Z; Guo Q
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1276-81. PubMed ID: 22079759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors.
    Yu LM; Zhang XR; Li XB; Yang Y; Wei HY; He XX; Gu LQ; Huang ZS; Pommier Y; An LK
    Eur J Med Chem; 2015 Aug; 101():525-33. PubMed ID: 26188908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Thapa U; Thapa P; Karki R; Yun M; Choi JH; Jahng Y; Lee E; Jeon KH; Na Y; Ha EM; Cho WJ; Kwon Y; Lee ES
    Eur J Med Chem; 2011 Aug; 46(8):3201-9. PubMed ID: 21601964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers.
    Janockova J; Korabecny J; Plsikova J; Babkova K; Konkolova E; Kucerova D; Vargova J; Koval J; Jendzelovsky R; Fedorocko P; Kasparkova J; Brabec V; Rosocha J; Soukup O; Hamulakova S; Kuca K; Kozurkova M
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):877-897. PubMed ID: 30938202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.